New oral multitargeted antiangiogenics in non-small-cell lung cancer treatment

Bruno Gori, Serena Ricciardi, Alberto Fulvi, Ester Del Signore, Filippo De Marinis

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Non-small-cell lung cancer is a particularly aggressive cancer. Combination chemotherapy remains the standard therapy for patients with advanced or metastatic disease. However, despite the available treatment options for patients who progress beyond first-line therapy, prognosis remains poor. Angiogenesis is a tightly regulated process controlled by a delicate balance between pro- and antiangiogenic factors and their receptors; tumors induce angiogenesis by disrupting this balance and secreting various growth factors. Inhibition of tumor-related angiogenesis has become an attractive target for anticancer therapy. Antiangiogenic strategy includes monoclonal antibodies against VEGF and VEGF receptor and small molecule inhibitors of VEGF tyrosine kinase activity (tyrosine kinase inhibitors). Tyrosine kinase inhibitors are orally active, small molecules that represent a new class of drugs with a relatively high safety profile. They are targeted therapies that play their anticancer role interfering with specific cell signaling. This review focuses on such oral antiangiogenic agents that have been approved and are in advanced clinical development for the treatment of patients with advanced non-small-cell lung cancer.

Original languageEnglish
Pages (from-to)559-573
Number of pages15
JournalFuture Oncology
Volume8
Issue number5
DOIs
Publication statusPublished - May 2012

Fingerprint

Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
Vascular Endothelial Growth Factor A
Play Therapy
Therapeutics
Neoplasms
Vascular Endothelial Growth Factor Receptor
Angiogenesis Inhibitors
Combination Drug Therapy
Intercellular Signaling Peptides and Proteins
Monoclonal Antibodies
Safety
Pharmaceutical Preparations

Keywords

  • angiogenesis
  • antiangiogenic therapy
  • biomarker
  • non-small-cell lung cancer
  • oral tyrosine kinase inhibitor
  • targeted agent

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

New oral multitargeted antiangiogenics in non-small-cell lung cancer treatment. / Gori, Bruno; Ricciardi, Serena; Fulvi, Alberto; Del Signore, Ester; De Marinis, Filippo.

In: Future Oncology, Vol. 8, No. 5, 05.2012, p. 559-573.

Research output: Contribution to journalArticle

Gori, Bruno ; Ricciardi, Serena ; Fulvi, Alberto ; Del Signore, Ester ; De Marinis, Filippo. / New oral multitargeted antiangiogenics in non-small-cell lung cancer treatment. In: Future Oncology. 2012 ; Vol. 8, No. 5. pp. 559-573.
@article{e3c93776fc614f0e90a2d5ec20655920,
title = "New oral multitargeted antiangiogenics in non-small-cell lung cancer treatment",
abstract = "Non-small-cell lung cancer is a particularly aggressive cancer. Combination chemotherapy remains the standard therapy for patients with advanced or metastatic disease. However, despite the available treatment options for patients who progress beyond first-line therapy, prognosis remains poor. Angiogenesis is a tightly regulated process controlled by a delicate balance between pro- and antiangiogenic factors and their receptors; tumors induce angiogenesis by disrupting this balance and secreting various growth factors. Inhibition of tumor-related angiogenesis has become an attractive target for anticancer therapy. Antiangiogenic strategy includes monoclonal antibodies against VEGF and VEGF receptor and small molecule inhibitors of VEGF tyrosine kinase activity (tyrosine kinase inhibitors). Tyrosine kinase inhibitors are orally active, small molecules that represent a new class of drugs with a relatively high safety profile. They are targeted therapies that play their anticancer role interfering with specific cell signaling. This review focuses on such oral antiangiogenic agents that have been approved and are in advanced clinical development for the treatment of patients with advanced non-small-cell lung cancer.",
keywords = "angiogenesis, antiangiogenic therapy, biomarker, non-small-cell lung cancer, oral tyrosine kinase inhibitor, targeted agent",
author = "Bruno Gori and Serena Ricciardi and Alberto Fulvi and {Del Signore}, Ester and {De Marinis}, Filippo",
year = "2012",
month = "5",
doi = "10.2217/fon.12.48",
language = "English",
volume = "8",
pages = "559--573",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "5",

}

TY - JOUR

T1 - New oral multitargeted antiangiogenics in non-small-cell lung cancer treatment

AU - Gori, Bruno

AU - Ricciardi, Serena

AU - Fulvi, Alberto

AU - Del Signore, Ester

AU - De Marinis, Filippo

PY - 2012/5

Y1 - 2012/5

N2 - Non-small-cell lung cancer is a particularly aggressive cancer. Combination chemotherapy remains the standard therapy for patients with advanced or metastatic disease. However, despite the available treatment options for patients who progress beyond first-line therapy, prognosis remains poor. Angiogenesis is a tightly regulated process controlled by a delicate balance between pro- and antiangiogenic factors and their receptors; tumors induce angiogenesis by disrupting this balance and secreting various growth factors. Inhibition of tumor-related angiogenesis has become an attractive target for anticancer therapy. Antiangiogenic strategy includes monoclonal antibodies against VEGF and VEGF receptor and small molecule inhibitors of VEGF tyrosine kinase activity (tyrosine kinase inhibitors). Tyrosine kinase inhibitors are orally active, small molecules that represent a new class of drugs with a relatively high safety profile. They are targeted therapies that play their anticancer role interfering with specific cell signaling. This review focuses on such oral antiangiogenic agents that have been approved and are in advanced clinical development for the treatment of patients with advanced non-small-cell lung cancer.

AB - Non-small-cell lung cancer is a particularly aggressive cancer. Combination chemotherapy remains the standard therapy for patients with advanced or metastatic disease. However, despite the available treatment options for patients who progress beyond first-line therapy, prognosis remains poor. Angiogenesis is a tightly regulated process controlled by a delicate balance between pro- and antiangiogenic factors and their receptors; tumors induce angiogenesis by disrupting this balance and secreting various growth factors. Inhibition of tumor-related angiogenesis has become an attractive target for anticancer therapy. Antiangiogenic strategy includes monoclonal antibodies against VEGF and VEGF receptor and small molecule inhibitors of VEGF tyrosine kinase activity (tyrosine kinase inhibitors). Tyrosine kinase inhibitors are orally active, small molecules that represent a new class of drugs with a relatively high safety profile. They are targeted therapies that play their anticancer role interfering with specific cell signaling. This review focuses on such oral antiangiogenic agents that have been approved and are in advanced clinical development for the treatment of patients with advanced non-small-cell lung cancer.

KW - angiogenesis

KW - antiangiogenic therapy

KW - biomarker

KW - non-small-cell lung cancer

KW - oral tyrosine kinase inhibitor

KW - targeted agent

UR - http://www.scopus.com/inward/record.url?scp=84861738322&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861738322&partnerID=8YFLogxK

U2 - 10.2217/fon.12.48

DO - 10.2217/fon.12.48

M3 - Article

C2 - 22646771

AN - SCOPUS:84861738322

VL - 8

SP - 559

EP - 573

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 5

ER -